3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Endocrine
1
Conditions
Breast Neoplasms
144
Neoplasm Metastasis
16
Neoplasms
8
Advanced Breast Cancer
8
Ovarian Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Breast Cancer Metastatic
5
Prostatic Neoplasms
4
Endometrial Neoplasms
4
Recurrence
3
Hereditary Sensory and Autonomic Neuropathies
3
Lung Neoplasms
2
Hyperglycemia
2
Exanthema
2
Estrogen Receptor-positive Breast Cancer
2
Colorectal Neoplasms
2
Carcinoma, Lobular
2
Breast Neoplasms, Male
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Endometrial Stromal
1
Salivary Gland Neoplasms
1
Recurrent Uterine Corpus Carcinoma
1
Neoplastic Cells, Circulating
1
Interventions
Fulvestrant
2
Alpelisib
2
exemestane
1
dapagliflozin
1
Vildagliptin
1
Tamoxifen
1
Metformin
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Hyperglycemia
×
Fulvestrant
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts